Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraxol in advanced malignancies
NCT02730481Phase 1Completed
- Sponsor
- Athenex
- Start
- Mar 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel + encequidar in solid tumor, sponsored by Athenex. Primary endpoint: Maximum Tolerated Dose at 20 weeks. Started Mar 2016; status: completed.
02
Drugs
paclitaxel + encequidar
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02730481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730481.